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ACTIVATION of the inflammatory response system and
varied levels of cytokines in acute schizophrenia have
been suggested by recent studies. Psychopharmaco-
logic agents can differentially effect cytokine produc-
tion,  which  suggests  that  therapeutic  function  of
neuroleptics may involve immunomodulation.
The present study was carried out to examine: (i)
serum concentrations of interleukin (IL)-1b , soluble
interleukin-2 receptor (sIL-2R), IL-6, IL-8 and tumour
necrosis factor (TNF)-a in schizophrenic patients; (ii)
their  relation  with  psychopathological  assessment;
and (iii) the relation of the initial cytokine levels with
responsiveness to risperidone therapy.
Thirty-four  drug-free  schizophrenic  patients  with
acute exacerbation and 23  age- and gender-matched
healthy controls  were recruited  for  this study.  Psy-
chopathological  assessments  at  admission  and
throughout risperidone  treatment  for  60  days  were
recorded. Serum cytokine concentrations were deter-
mined with chemilumunescence assays.
According to our results, serum IL-1b , sIL-2R, IL-6,
IL-8  and  TNF-a concentrations  adjusted  for  age,
gender,  body  mass  index  and  smoking  were  no
different in patients with schizophrenia and controls
and among subtypes of schizophrenia. However, the
initial  TNF-a concentrations had a significant effect
on  Brief  Psychiatric  Rating  Scale  and  Scale  Assess-
ment of Positive Symptoms  scores. The initial cyto-
kine  concentrations  of  the  patients  responsive  to
risperidone  were  not  significantly  different  from
those of non-responsive patients.
The present study demonstrates that plasma levels
of  IL-1b ,  sIL-2R,  IL-6,  IL-8  and  TNF-a adjusted  for
confounding  factors  are  not  altered  in  drug-free
schizophrenic  patients  at  acute  exacerbation.  We
suggest  that,  if  cytokine  production  is  altered  in
schizophrenia, these  alterations  may  not  be detect-
able in systemic circulation. According to our results,
the therapeutic effect of risperidone is not related to
basal levels  of  the  aforementioned cytokines.  How-
ever, serum TNF-a may contribute to symptomatology
in schizophrenia.
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Introduction
Over the past decade, as immunologic, neurochem-
ical  and  neuroendocrine activities of  the  cytokines
involving  the  brain  and  their  behavioural  effects
have  been  demonstrated,  research  concerning  the
role  of  cytokines  in  schizophrenia  has  expanded.1
Activation of  the  inflammatory  response system  in
acute  schizophrenia has been  suggested  by  several
recent studies. Schizophrenic patients have aberrant
proportions of  immuno-competent  cells  and  varied
levels of cytokines, especially proinflammatory inter-
leukin (IL)-6, IL-1 and tumour necrosis factor (TNF)-
a , in their peripheral blood or cerebrospinal fluid.2
A decrease in mitogen-stimulated IL-2 production by
peripheral  blood  mononuclear  cells  and  elevated
levels of soluble interleukin-2 receptor (sIL-2R) were
also  observed.3,4 Theoretically,  alterations  in  the
levels of cytokines can simply be a consequence of
mental  stress  or  sleep  deprivation  associated  with
the  onset  or  exacerbation  of  the  disease.  On  the
contrary,  they  can  modify  metabolism  of  neuro-
transmitters  and  neuroendocrine  hormones,  and
influence  neural  development  and  neurodegenera-
tion,  as  supported  by  findings  in  fundamental
neuroscience.1,2,5
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schizophrenia, belongs to the chemoattractant cyto-
kines (namely,  the chemokine subfamily)  and takes
part  in  immune  response,  cell  adhesion  and
angiogenesis.6
Cytokines,  which  were  discovered  as  humoral
mediators  of  cell-to-cell  interactions  within  the
immune system, have been found to be key factors for
the host responses that are mediated by the central
nervous system, which include fever and activation of
the  hypothalamic–pituitary–adrenal  system.  Behav-
ioural-activating effects of certain cytokines like the
somnogenic  activity  of  IL-1  and  TNF-a and  the
suppresser effects of IL-1b , IL-8 and TNF-a on appetite
are also demonstrated.1 In an animal study, IL-1-, IL-2-
and IL-6-treated mice displayed significant differences
in  exploration.7 In  schizophrenic patients, different
patterns of cytokine production and psychotic behav-
iour  such  as  paranoid  behaviour  and  IL-10  are
suggested.8 Furthermore, the administration of cyto-
kines  may  induce  numerous  psychiatric  symptoms
such  as fatigue,  apathy,  depressive mood and  delu-
sions.1 Therefore, it is reasonable to assume that the
presumed immunopathology in psychiatric disorders
might lead to alterations in circulating cytokine levels.
Although  the aetiology,  pathogenesis and  mecha-
nism of schizophrenia has remained elusive, efficient
treatment  with  neuroleptic  medication  for  acute
schizophrenia has been proved beyond doubt. Actions
of  these drugs and biochemical and immunological
changes  that  occur  in  response  to  treatment  have
advanced our understanding of  the basis of  schizo-
phrenia. However, 20–40% of the patients are resistant
to  standard  antipsychotic  treatments,  suggesting  a
contribution  of  different  mechanisms  in  individual
patients.9With this point of view, response to a specific
therapy may be a tool for understanding pathophysiol-
ogy  of  the  disease.  Risperidone  is  a  benzisoxazole
derivate, chemically unrelated to any other currently
available antipsychotic drug. Risperidone, like cloza-
pine,  is  a  potent  5-hydroxytryptamine  (5-HT)2 and
relatively weak D2 dopamine receptor antagonist.9
Although very limited, several studies have repor-
ted  changes  in  the  levels  of  specific  cytokines  in
conjunction with psychopharmacologic agents, sug-
gesting  that therapeutic action of neuroleptics may
involve  immunomodulation.  In  vitro studies  have
shown that chlorpromazine has an inhibitory effect
on the production of  IL-2, TNF-a and interferon by
human  lymphocytes.  In  humans,  neuroleptic  treat-
ment  has  been  associated with  an  increase  in  the
serum levels of sIL-2R and a decrease in the levels of
sIL-6R.1,10 The  immunomodulatory  action of risper-
idone involving the Clara cell protein and sIL-2R has
also  been  suggested.11 However,  associations
between changes in the levels of cytokines and the
therapeutic  response  have  not  been  firmly
established.
In this study, serum IL-1b , sIL-2R, IL-6, IL-8 and TNF-
a concentrations  of  34  drug-free  schizophrenic
patients  were  analysed.  Psychopathological  assess-
ments at admission and throughout risperidone treat-
ment for 60 days were recorded to evaluate whether
cytokine levels  have any effect on Brief  Psychiatric
Rating  Scale  (BPRS),  Scale  Assessment  of  Positive
Symptoms (SAPS) and Scale Assessment of Negative
Symptoms (SANS) scores, and on improvement ach-
ieved with an atypical neuroleptic risperidone.
Material and methods
Subjects
The  study  was  conducted  at  Gaziantep  University,
Faculty of Medicine (Department of Psychiatry, and
Department of  Biochemistry  and  Clinical  Biochem-
istry) in 2000. Informed consent was obtained from
all subjects according to the Helsinki declaration as
revised  in  1996.  Thirty-four  patients  with  schizo-
phrenia  (15  males and  19  females)  were recruited.
The mean age was 33.1 years (range, 17–72 years).
The mean duration of illness  was 5.9  years (range,
1.0–25.0 years). Eleven patients were smokers; none
of them were alcohol consuming.
Healthy  non-psychiatric  controls  (n =23)  were
recruited from the hospital staff. Eight of the controls
were male and 15 were female. The mean age was
29.2 years (range, 18–44 years). Fifteen were smok-
ers; none of them were alcohol consuming. None of
the  healthy  controls  had  a  history  of  psychiatric
disorder, drug abuse or dependence, serious medical
conditions or seizure disorders.
Protocol
Prior to admission, patients were treated with typical
neuroleptic  drugs. After  withdrawal of  typical  neu-
roleptics for 1 week, blood samples were taken and
initial  psychopathologic  assessment  was  recorded,
followed  by  treatment  with  4mg  daily  doses  of
risperidone for 60 days.
The  initial  psychopathological assessment  (BPRS,
SANS, SAPS) at day 1 (T1) was reviewed at every point
of investigation, at day 15 (T2), at day 30 (T3) and at
day 60 (T4). All patients were monitored for somatic
illness throughout the investigation period and were
excluded if symptoms of infections or symptoms of
systemic  somatic  illness  were  present.  Thirty-four
patients were included according to these criteria.
Clinical assessment
A  DSM-IV  diagnosis  of  chronic  schizophrenia  was
established on the basis  of independent structured
clinical  interviews  and  a  review  of  records  by  a
qualified psychiatrist that included the BPRS.12 Patients
with any form of psychiatric comorbidity including
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the  criteria for  paranoid,  14  for  residual,  three  for
disorganised and one patient for an undifferentiated
form of acute or chronic schizophrenia. SAPS and SANS
were  also  recorded  throughout  the  investigation
period. Patients with a 20% decrease in BPRS, SANS and
SAPS at  T4 were accepted as responsive to risperidone.
Age of the schizophrenia onset was defined as the
age at which symptoms first appeared as reported by
the patient, the family or medical staff.
Experimental
Blood  samples  were  collected  using  standard  ven-
ipuncture  technique  between  9:30  and  11:00  a.m.
after 12h fast. Serum samples were separated imme-
diately  after  centrifugation  at  +4°C,  2000  ´ g for
10min and stored at –20°C until analysis, which was
performed in the same run to avoid inter-run analyt-
ical variation. Serum IL-1b , sIL-2R, IL-6, IL-8 and TNF-a
levels  were  determined  with  chemiluminescence
enzyme immunometric assays on an Immulite Immu-
noassay Analyser (Immulite IL-1b ®, sIL-2R®, IL-6®, IL-
8® and TNF-a ® assays; DPC, Los Angeles, CA, USA).
The analytical sensitivities of IL-1b , sIL-2R, IL-6, IL-8
and TNF-a assays were 1.5pg/ml, 10U/ml, 1.0pg/ml,
2.0pg/ml and 1.7pg/ml, respectively, and the lower
reportable ranges were 5.0pg/ml, 50U/ml, 5.0pg/ml,
5.0pg/ml  and  4.0pg/ml,  respectively.  The  cross-
reactivities of IL-1a , IL-2, IL-2R, IL-4, IL-5, IL-6, IL-8, IL-
10, TNF-a and  interferon-g for  the  IL-1b assay,  the
cross-reactivities of IL-1b , IL-2, IL-6, IL-8, IL-10, TNF-a
and  interferon-g for  the  sIL-2R  assay,  the  cross-
reactivities of IL-1b , IL-2, IL-2R, IL-4, IL-6, TNF-a and
interferon-g for the IL-8 assay, and the cross-reactiv-
ities of IL-1b , IL-2, IL2R, IL-4, IL-6, IL-8, IL-10 and IL-13
for the TNF-a assay were non-detectable. The cross-
reactivities of IL-1a , IL-1b , IL-2, IL-4, IL-8, TNF-a and
interferon-g for  the  IL-6  assay  were  £ 0.065%  as
reported  by  the  manufacturer.  Immulite  cytokine
controls were included in each analytical run. Intra-
assay and inter-assay precision performances of  the
assays were determined on 10 replicates in a single
run and in 20 different runs, respectively, from the
quality control data of the laboratory. Coefficients of
variation obtained were within the 3.4–8.8% range.
Statistical
Data  are  presented  as  mean  ±  SEM  or  median
(minimum–maximum) when n £  30. Because IL-1b ,
sIL-2R,  IL-6 and IL-8 distribution was skewed right-
ward,  a  natural  log  transformation  was  applied  to
normalise the data for analysis. A general linear model
was used to consider case–control differences after
adjustment for other factors and covariates on trans-
formed data. The paired-samples t-test for psychopath-
ological assessment and the Kruskal–Wallis test was
performed for subgroups. Case–control differences in
nominal data (gender, smoking) were evaluated with
the  chi-squared  test. Two-tailed  p <  0.05  was  con-
sidered  significant.  Analyses  and  illustrations  were
performed with SPSS 9.0 (SPSS Inc., Chicago, IL, USA)
and  MedCalc  (Mariakerke,  Belgium)  statistical  soft-
ware programs.
Results
The baseline characteristics of the study participants
are presented in Table 1. Because of matching criteria,
Schizophrenia and cytokines
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Table 1. Characteristics of the study participants
Patients (n = 34) Controls (n = 23)
Gender (male/female) 15/19 8/15
Age (years)
a 30 (17–72) 28 (18–44)
Smoker (n) 11, 32.3% 15, 65.2%
Body mass index (kg/m
2)
a 23.4 (18.3–39.1) 22.3 (17.2–39.5)
a Data presented as median (minimum–maximum).
Table 2. Psychopathological assessments  of the patients with schizophrenia throughout the investigation period (mean ±
SEM)
T1 (day 1) T2 (day 15) T3 (day 30) T4 (day 60)
BPRS* 45.6 ± 1.3 36.2 ± 1.6 28.9 ± 1.6 24.0 ± 1.8
SANS† 79.2 ± 5.7 70.1 ± 5.3 58.1 ± 4.3 51.4 ± 4.0
SAPS* 58.4 ± 4.4 43.7 ± 3.6 32.8 ± 3.3 26.4 ± 3.2
BPRS, Brief Psychiatric Rating Scale; SAPS, Scale Assessment of Positive Symptoms; SANS, Scale Assessment of Negative Symptoms.
* p < 0.001 for T1 versus T2, T2 versus T3, T3 versus T4, and T1 versus T4.
† p < 0.001 for T1 versus T2, T2 versus T3 and T1 versus T4; p < 0.005 T3 versus T4.no statistically significant difference was noted in age,
gender, smoking and body mass index (BMI).
Psychopathology
At admission (T1), the BPRS, SANS and SAPS scores
were (mean ± SEM) 45.6 ± 1.3, 79.2 ± 5.7 and 58.4 ±
4.4, respectively. During 60 days of in-patient treat-
ment,  BPRS,  SANS  and  SAPS  scores  improved  sig-
nificantly from T1 to T2, from T2 to T3, and from T3 to
T4 (Table 2). Total  improvements  (T1 to T4)  of the
scores were 46.2 ± 4.3, 33.0 ± 4.0 and 53.0 ± 5.1% (p
< 0.001), respectively.
Immunological findings
Plasma interleukin levels were measured in patients
with  schizophrenia  at T1 and  compared  with  the
controls. A statistically significant difference was not
observed for serum log sIL-2R, log IL-1b , log IL-6, log
IL-8 and TNF-a adjusted for age, gender, smoking and
BMI  (Table  3  and  Figs.  1–3).  A  significant  inter-
correlation between TNF-a and IL-8 was detected only
in the patient group (r = 0.486, p < 0.006).
Plasma interleukin  levels  (T1)  were  not  different
among  subtypes  of  schizophrenia  (p >  0.05)
(Table 4).
Nominal data and cytokines
In  the  case  group,  no  significant  correlation  was
seen between cytokine concentrations and age, BMI
and duration of the disease, and no difference was
observed  in  relation  to  gender,  smoking,  positive
family history and education.
Relation of psychopathology and cytokines
Regarding  psychopathological  assessment  at  T1,
only TNF-a concentrations  had  a  significant  effect
on  BPRS  and  SAPS  according  to  the  general  linear
model that included age, smoking, BMI, gender and
subtypes  of  schizophrenia  (p =  0.019  and  p =
0.030) (Table 5).
Responsiveness to risperidone and cytokines
The  initial  cytokine  concentrations of  the  patients
responsive  to  risperidone  were  not  significantly
different from those of non-responsive patients.
A. B. Erba Ægci et al.
112 Mediators of Inflammation · Vol 10 · 2001
Table  3.  Serum  median  (minimum–maximum) interleukin
concentrations  of  the patients with schizophrenia and the
healthy control group at T1
Patients (n = 34) Controls (n = 23)
sIL-2R (U/ml) 583 (262–3567) 625 (303–858)
IL-1b (pg/ml) 5.0 (5.0–11.6) 5.0 (5.0–5.0)
IL-6 (pg/ml) 5.0 (5.0–13.2) 5.0 (5.0–7.7)
IL-8 (pg/ml) 10.2 (5.0–1683.0) 8.5 (5.0–233.0)
TNF-a (pg/ml) 6.3 (4.0–10.9) 6.8 (4.0–14.1)
sIL-2R,  Soluble  interleukin-2  receptor;  IL,  interleukin;  TNF,  tumour
necrosis factor.
FIG. 1. Serum tumour necrosis factor-alpha (TNF-a ) concentrations in the schizophrenic patients and the healthy controls. The
central box represents the values from the 25th to 75th percentiles. The middle line represents the median. A line extends from
the minimum to the maximum values, excluding extreme values.Discussion
In the present study, a significant difference of IL-1b ,
sIL-2R,  IL-6,  IL-8  and  TNF-a was  not  observed  in
schizophrenic  patients  compared  with  the  healthy
controls.  Although investigators reported altered circu-
lating levels and in vitro production of cytokines in
schizophrenia,  the  respective  evidence  is  not  con-
sistent.  Several  studies  have  found  a  decrease  in
mitogen-stimulated  IL-2  production  by  peripheral
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FIG. 2. Serum soluble interleukin-2 receptor (sIL-2R) concentrations in the schizophrenic patients and the healthy controls on
a semi-logarithmic scale. The central box represents the values from the 25th to 75th percentiles. The middle line represents
the median. A line extends from the minimum to the maximum values, excluding extreme values.
FIG. 3. Serum interleukin (IL)-8 concentrations in the schizophrenic patients and the healthy controls on a semi-logarithmic
scale. The central box represents the values from the 25th to 75th percentiles. The middle line represents the median. A line
extends from the minimum to the maximum values, excluding extreme values.blood mononuclear cells, which is the most frequently
confirmed  finding  in  the  immunology  of  schizo-
phrenia.3,13–15 Elevated levels of the sIL-2R in periph-
eral  blood,  a  sign  that  also  indicates  lymphocyte
activation, were also repeatedly observed in schizo-
phrenia,4,16,17 whereas  other  studies  failed  to  find
differences  between  patients  and  healthy  con-
trols.10,18,19 Moreover,  circulating  levels  of  other
leukocyte  activation  markers  such  as  SCD14  and
SCD23  were  not higher than controls.20 Other fre-
quently  replicated  immune  alterations  include  an
increase  in  serum  IL-6  concentrations  in  schizo-
phrenia.21,22 However,  some  studies  reported  no
difference or even decreased IL-6 levels in drug-free
patients.23–27 Results regarding levels and/or produc-
tion of IL-1 and TNF-a have been inconclusive, and are
reported  to  be  increased,  decreased  or  unchan-
ged.18,20,25,26,28 Haack et al. have shown that when
confounding factors like age, gender, BMI, smoking
habits and prior medication are taken into account,
plasma  levels  of  IL-6,  TNF-a and  sIL-2R  are  not
different.29 Our  results  that  show  no  difference  in
circulating IL-1b , sIL-2R, IL-6, IL-8 and TNF-a concen-
trations adjusted for age, gender and smoking in drug-
free  schizophrenic  patients  confirm  this  previous
study.  However  these  findings  do  not  definitively
exclude  a  pathophysiological  role  for  cytokines  in
schizophrenia because they effect primarily the brain
where the regulation of cytokine production differs
considerably from the periphery. However, the pres-
ent study suggests that if cytokine production is altered
in schizophrenia, these alterations may not be detect-
able in the systemic circulation.
The second major finding of this study is that TNF-a
may  be  associated with  symptomatology  of  schizo-
phrenia:  BPRS  and  SAPS.  Although  part  of  the
response of the organism to an infection or injury is
local and occurs at the cellular and molecular levels,
another part occurs at the level of the organism and
involves  specific  adaptive  behaviours  such  as
increased sleep, decreased appetite and sexual drive,
which  may  be  at  least  partly  attributed to  specific
effects of cytokines. There is growing evidence that
TNF-a may  be  associated  with  somnolence  and
anorexia. Additionally, the stimulatory effect of TNF-a
on hypothalamic–pituitary–adrenal activity, which is
a  feedback  mechanism  to  suppress  an  otherwise
exaggerated  immune/inflammatory  response,  could
effect symptomatology on a disturbed neurochemical
basis  in  schizophrenia.1 Naudin  et  al. previously
found higher levels of TNF-a in schizophrenic patients
with no relation between global,  negative and pos-
itive subscale scores. However, in that study, a small
proportion of patients who had high TNF-a levels also
had elevated IL-6 levels, suggesting a systemic cause
for  elevation  of  these  proinflammatory  cytokines,
which in turn may lead to discordance of psychopath-
ological assessment and TNF-a .20
In the present study, a relation between improve-
ment of psychopathological assessment during risper-
idone treatment and the initial cytokine levels was not
observed. Previously, an immunosuppresive effect of
neuroleptics  through  suppression  of  IL-6-  or  IL-
6R-related  mechanisms,29 clozapine-induced  incre-
ments in plasma sCD8, IL-6, CC16, IL-1RA1, sTNF-R2
and sIL-2R concentrations,30,31 and increased serum
sIL-2R  and  decreased sIL-6R  levels1 were  reported,
whereas no differences in IL-2 and IFN-g production
between  unmedicated  and  medicated  schizophren-
ics32 were observed. Chronic treatment with risper-
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Table  4.  Serum  median  (minimum–maximum)  interleukin  concentrations  of  the  patients  with  different  subtypes  of
schizophrenia
Paranoid (n = 16) Residual (n = 14) Disorganised (n = 3) Controls (n = 23)
sIL-2R (U/ml) 604 (307–2030) 642 (262–3567) 545 (410–590) 625 (303–858)
IL-1b (pg/ml) 5.0 (5.0–6.0) 5.0 (5.0–11.6) 5.0 (5.0–5.2) 5.0 (5.0–5.0)
IL-6 (pg/ml) 5.0 (5.0–13.2) 5.0 (5.0–5.0) 5.0 (5.0–5.0) 5.0 (5.0–7.7)
IL-8 (pg/ml) 8.1 (5.0–647.0) 9.3 (5.0–1683.0) 27.8 (19.1–362.0) 8.5 (5.1–233.0)
TNF-a (pg/ml) 6.1 (4.0–10.8) 6.7 (4.0–9.5) 5.1 (4.0–10.9) 6.8 (4.0–14.1)
sIL-2R, Soluble interleukin-2 receptor; IL, interleukin; TNF, tumour necrosis factor.
Table 5. Significant relations of TNF-a and psychopathological assessments at T1
ANCOVA BPRS (T1)
F p
SAPS (T1)
F p
TNF-a 7.41 0.019 6.10 0.030
BPRS, Brief Psychiatric Rating Scale; SAPS, Scale Assessment of Positive Symptoms.idone was reported to normalise lower plasma Clara
cell  protein  and  increase plasma  sIL-2R  in  a  cross-
sectional  study.11 Thus,  the  evidence  that  antipsy-
chotic  agents  may  modulate  cytokines  in  schizo-
phrenia is contradictory. Our study does not include
cytokine levels after treatment but demonstrates that
the initial cytokine levels are not indicative of patients
responsive to risperidone treatment, suggesting that
therapeutic  action  of  risperidone  may  not  involve
cytokines investigated.
The present study has some methodological limita-
tions that might contribute to the fact that we did not
find a major impact of schizophrenia on IL-6 and IL-1b
levels. The majority of the patients and the control
group  had  lower  plasma  levels  than  the  detection
limit of the assays, which raises the possibility that
group differences might be present below the detec-
tion  limit. This  possibility  is  supported  by  studies
using  more  sensitive  IL-6  and  IL-1b assays  and
reporting  increased  levels,  although  other  studies
using sensitive assays found no differences between
schizophrenic cases and  controls.24 It  is  also  note-
worthy that studies reporting differences for IL levels
had quite large standard deviations, suggesting con-
siderable  heterogeneity  in  the  levels  of  individual
patients.10,21,22,24 Therefore, immune alterations may
be limited to a special subset of patients.
In summary,  the present study demonstrates that
circulating  levels  of  cytokines  are  no  different  in
patients with schizophrenia when confounding fac-
tors like age, gender, smoking and BMI are taken into
account. Immune alterations observed in the previous
studies may indicate a special subset of patients or
simply result from confounding factors, medications
or  somatic  causes.  Therefore,  we  conclude  that
plasma IL-1b , sIL-2R, IL-6, IL-8 and TNF-a concentra-
tions yield little, if any, evidence for immunopathol-
ogy in schizophrenia. However, TNF-a may contribute
to schizophrenic symptomatology. According to our
results, cytokine levels are not indicative of a special
subset of patients responsive to risperidone.
ACKNOWLEDGEMENTS. The authors gratefully  acknowledge the excellent
technical assistance of Mustafa Da Æ gdeviren and Yakup Tuncel.
References
1. Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical
psychiatry. Am J Psychiatry 2000; 157: 683–694.
2. Katila  H, H¨ anninen K, Hurme M. Polymorphisms  of the interleukin-1
gene complex in schizophrenia. Mol Psychiatry 1999; 4: 179–181.
3. Arolt V, RothermundtM, Wandinger KP, Kirchner H. Decreased in vitro
production  of  interferon-gamma  and  interleukin-2 in  whole  blood  of
patients  with  schizophrenia  during  treatment.  Mol  Psychiatry 2000;
5:150–158.
4. Gaughran F, O’Neill E, ColeM, Collins K, Daly RJ, Shanahan F. Increased
soluble  interleukin  2 receptor  levels in schizophrenia.  Schizophr  Res
1998; 29: 263–267.
5. Prolo P, Licinio J. Cytokines in affective disorders and schizophrenia: new
clinical and genetic findings. Mol Psychiatry 1999; 4: 109–111.
6. Santos-RosaM, Bienvenu J, Whicher J. Cytokines. In: Burtis CA, Ashwood
ER,  eds.  Tietz  Textbook  of  Clinical  Chemistry.  London:  Saunders
Company, 1999:541–617.
7. Zalcman S, Murray L, Dyck DG, Greenberg AH, Nance DM. Interleukin-2
and –6 induce  behavioral-activating  effects in mice. Brain  Res 1998;
811: 111–121.
8. Cazzullo CL, Scarone S, Grassi B, et al. Cytokines production in chronic
schizophrenia  patients  with  or  without  paranoid  behaviour.  Prog
Neuropsychopharmacol Biol Psychiatry 1998; 22: 947–957.
9. Schulz SC, Buckley PF. Treatment-resistant schizophrenia. In: Hirsch SR,
Weinberger  DR,  eds  Schizophrenia.  London:  Blackwell  Science,
1995:469–484.
10. Muller  N,  EmplM,  RiedelM,  SchwarzM,  Ackenheil  M.  Neuroleptic
treatment increases soluble IL-2 receptors and  decreases soluble  IL-6
receptors in schizophrenia. Eur Arch Psychiatry Clin Neurosci 1997;
247: 308–313.
11. MaesM, Bosmans E, Ranjan R, et al. Lower plasma CC16, a natural anti-
inflammatory  protein,  and  increased  plasma  interleukin-1  receptor
antagonist in schizophrenia: effects of antipsychotic drugs.  Schizophr
Res 1996; 21: 39–50.
12. Overal JE, Gorhan DR. The brief psychiatric rating scale. Psychol Reports
1962; 10: 799–812.
13. Ganguli  R, Rabin BS, Belle  SH. Decreased interleukin-2 production  in
schizophrenic patients. Biol Psychiatry 1989; 26: 424–427.
14. Ganguli R, Brar JS, Chengappa KR, et al. Mitogen-stimulated interleukin-2
production in never-medicated, first-episode schizophrenic patients. The
influence of age at onset and negative symptoms. Arch Gen Psychiatry
1995; 52: 668–672.
15. Villemain F, Chatenoud L, Galinowski A, et al. Aberrant T cell-mediated
immunity  in  untreated schizophrenic  patients:  deficient  interleukin-2
production. Am J Psychiatry 1989; 146: 609–616.
16. Ganguli R, Rabin BS. Increased serum interleukin 2 receptor concentra-
tion in schizophrenic and brain-damaged subjects. Arch Gen Psychiatry
1989; 46: 292.
17. MaesM, Meltzer HY, Buckley P, Bosmans E. Plasma-soluble interleukin-2
and  transferrin  receptor  in  schizophrenia  and  major  depression.  Eur
Arch Psychiatr Clin Neurosci 1995; 244: 325–329.
18. Baker I, Masserano J, Wyatt RJ. Serum cytokine concentrations in patients
with schizophrenia. Schizophr Res 1996; 20: 199–203.
19. Wilke I, Arolt V, RothermundtM, Weitzsch Ch, HornbergM, Kirchner H.
Investigations  of  cytokine  production  in  whole  blood  cultures  of
paranoid and residual schizophrenic patients. Eur Arch Psychiatr Clin
Neurosci 1996; 246: 279–284.
20. Naudin J, Capo C, Giusano B, Mege JL, Azorin JM. A differential role for
interleukin-6 and tumor necrosis factor-a in schizophrenia? Schizophr
Res 1997; 26: 227–233.
21. Van Kammen DP, McAllister-Sistilli CG,  Kelley ME, Gurklis  JA, Yao JK.
Elevated  interleukin-6  in  schizophrenia.  Psychiatr  Res 1999;  87:
129–136.
22. Lin A, Kenis G, Bignotti S, et al. The inflammatory response system in
treatment-resistant schizophrenia: increased serum interleukin-6. Schiz-
ophr Res 1998; 32: 9–15.
23. Kim YK,  Kim  L,  Lee  MS.  Relationships between interleukins,  neuro-
transmitters  and  psychopathology  in  drug-free  male  schizophrenics.
Schizophr Res 2000; 44: 165–175.
24. Shintani F, Kanba S, Maruo N, et al. Serum interleukin-6 in schizophrenic
patients. Life Sci 1991; 49: 661–664.
25. Xu  HM, Wei  J,  Hemmings  GP.  Changes  of  plasma  concentrations of
interleukin-1a and interleukin-6 with neuroleptic treatment for schizo-
phrenia. Br J Psychiatry 1994; 164: 251–253.
26. Barak V, Barak Y, Levine J, Nisman B, Roisman I. Changes in interleukin-1b
and soluble interleukin-2 receptor levels in CSF and serum of schizophre-
nic patients. J Basic Clin Physiol Pharmacol 1995; 6: 61–69.
27. Wei J, Xu HM, Davies J, Ramchand CN,  Ramchand R, Hemmings GP.
Interleukins 1,2  and  6  in  the plasma  of  neuroleptic-free  and  treated
schizophrenic patients and their relatives. Schizophr Res 1992; 6: 140.
28. Monteleone  P,  FabrazzoM,  Tortorella  A,  Maj  M.  Plasma  levels  of
interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia:
effects of clozapine treatment. Psychiatr Res 1997; 71: 11–17.
29. MaesM, Bosmans E, Calabrese J, Smith R, Meltzer HY. Interleukin-2 and
interleukin-6  in schizophrenia and  mania:  effects of neuroleptics  and
mood stabilisers. J Psychiatr Res 1995; 29:141–152.
30. HaackM, Hinze-Selch T, Fenzel T, Kraus T, K¨ uhnM, Schuld A, Pollm¨ acher
T.  Plasma  levels  of  cytokines  and  soluble  cytokine  receptors  in
psychiatric  patients  upon  hospital  admission:  effects  of  confounding
factors and diagnosis. J Psychiatr Res 1999; 33: 407–418.
31. MaesM, Bosmans E, Kenis G, De Jong R. In vivo immunomodulatory
effects  of  clozapine  in  schizophrenia.  Schizophr  Res 1997;  26:
221–225.
32. RothermundtM, Arolt V, Leadbeater J, PetersM, Rundolf S, Kirchner H.
Cytokine production in unmedicated and treated schizophrenic patients.
Neuroreport 2000; 11: 3385–3388.
Received 13 March 2001;
Accepted 10 April 2001
Schizophrenia and cytokines
Mediators of Inflammation · Vol 10 · 2001 115